Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELATIVITY-106: nivolumab + relatlimab + bevacizumab versus nivolumab + bevacizumab in first-line advanced/metastatic hepatocellular carcinoma
CTR20223024Phase 2Suspended
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Relatlimab + nivolumab + bevacizumab with Relatlimab placebo + nivolumab + bevacizumab (2 arms). Primary endpoints: Dose-limiting toxicities and Objective response rate by BICR. Started Feb 2023; status: suspended.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20223024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223024.